AbbVie (ABBV)
(Delayed Data from NYSE)
$193.47 USD
-0.15 (-0.08%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $193.31 -0.16 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
ABBV 193.47 -0.15(-0.08%)
Will ABBV be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABBV
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
Other News for ABBV
Raise Cash And Sell Trash
EU pharma committee takes positive view on AbbVie, Merck, others
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE?) for the Treatment of Certain Adult Ovarian Cancer
AbbVie receives positive CHMP opinion for mirvetuximab soravtansine